Welcome!

News Feed Item

Inhalation & Nasal Spray Generic Drugs 2012

NEW YORK, Dec. 12, 2012  /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:


Inhalation & Nasal Spray Generic Drugs 2012
http://www.reportlinker.com/p01054642/Inhalation--Nasal-Spray-Generic-Drugs-2012 .html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Generic_Drug



It is no surprise then, that such high revenue originator drugs are attracting interest from prospective generic competitors. Unlike the oral generics market, however, where numerous companies typically compete for a revenue share, relatively few companies have the technology and expertise to compete in the market for generic inhalation and nasal spray products. But for those that are successful, there are significant revenue opportunities.



Overcoming the delivery challenge
While it is possible for companies to develop bioequivalent generic versions of nasal spray products, significant barriers remain to gaining entry into the more lucrative asthma/COPD market. The few generic inhalable products currently approved by the FDA in this therapy area are solutions, generally for delivery via a nebuliser. This is
partly due to developments in the delivery devices, following the phasing out of CFCs in metered dose inhalers (MDIs) in favour of devices that use the more ozone friendly
hydrofluoroalkane (HFA).



Developing a hand-held generic inhaler is no easy task. The bioavailability of the drug in the airway relies on a combination of the drug and the delivery device. To date, companies have been unable to gain marketing approval for bioequivalent generics in the US via the ANDA route. Some generics have been approved in the EU, but these are generally branded products that use proprietary inhalation devices and are, therefore, not pure generics and unlikely to be interchangeable at the pharmacy.



Key questions answered:

What delivery solutions have been found?
Which are the products to watch?
Who's making the running in this sector?




The answer to these and thousands of other key business questions can be found in this new market research study from Espicom. Essential reading for pharma executives, those in the generic field and the commercial community, this 128-page fact-filled report provides a complete and comprehensive review of the issues, trends, products and companies that are shaping the global market in this sector.



Development of generic alternatives in this sector will require some inspired thinking. Maybe not a generic approach at all?



Patent issues
The generic market is undergoing radical restructuring, with much rationalisation of the corporate landscape. In such a competitive environment, companies are now seeking not just new opportunities, but opportunities which combine good profit levels and a degree of product novelty ? both of which are available in the inhalation and nasal spray market.


Side stepping the bioequivalence problem
A few companies have avoided this problem by gaining approval for branded products that use proprietary inhalation devices. Among these are Teva, which has two successful branded asthma inhalers, Proair (salbutamol) and Qvar (beclomethasone dipropionate); and Orion, with its Easyhaler DPI. In October 2011, Teva became the first company to launch a generic salmeterol xinafoate 25mcg pMDI in the UK, following approval by the MHRA in April 2011. The UK marketing authorisation holder for the product, which is branded Neovent/Sereflo, is Neolab Ltd, a UK-based pharmaceutical development company. GSK has been quick to point out that Neovent is a branded product that is not identical to Serevent and, therefore, not an interchangeable generic. This is clearly Teva's approach: its beclomethasone dipropionate HFA nasal aerosol for the treatment of SAR will not be a generic and an NDA was submitted in May 2011 to the FDA.



Gearing up for Seretide/Advair?
Undoubtedly the biggest prize for generic manufacturers will be the current market leader: GSK's Seretide/Advair, which achieved revenue of US$8,247 million in 2011 –
nearly twice the value of its nearest competitor. GSK has US patents for Advair with expiry dates up to July 2025, although the combination patent expired in 2010. In Europe the UK patent has been revoked, but Seretide is protected by Supplementary Protection Certification in other countries until 2013.



At least two generic versions of Seretide/Advair are currently in development. Sandoz and Vectura are jointly developing VR315, a combination product that is widely thought to be generic Seretide/Advair. Sandoz currently has development and commercialisation rights in Europe and other markets, excluding the US. Vectura licensed the US rights to this product to an undisclosed pharmaceutical company in August 2011. Mylan is developing a generic fluticasone+salmeterol combination product, utilising Pfizer's dry powder inhaler delivery platform, following an agreement between the companies in 2011. Mylan is targeting a launch of its generic in Europe in 2015, followed by the US in 2016.

To order this report:
Generic_Drug Industry:
Inhalation & Nasal Spray Generic Drugs 2012

__________________________
Contact Nicolas: [email protected]
US: (805)-652-2626
Intl: +1 805-652-2626

 

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Docker containers have brought great opportunities to shorten the deployment process through continuous integration and the delivery of applications and microservices. This applies equally to enterprise data centers as well as the cloud. In his session at 20th Cloud Expo, Jari Kolehmainen, founder and CTO of Kontena, discussed solutions and benefits of a deeply integrated deployment pipeline using technologies such as container management platforms, Docker containers, and the drone.io Cl tool. H...
As more and more companies are making the shift from on-premises to public cloud, the standard approach to DevOps is evolving. From encryption, compliance and regulations like GDPR, security in the cloud has become a hot topic. Many DevOps-focused companies have hired dedicated staff to fulfill these requirements, often creating further siloes, complexity and cost. This session aims to highlight existing DevOps cultural approaches, tooling and how security can be wrapped in every facet of the bu...
For financial firms, the cloud is going to increasingly become a crucial part of dealing with customers over the next five years and beyond, particularly with the growing use and acceptance of virtual currencies. There are new data storage paradigms on the horizon that will deliver secure solutions for storing and moving sensitive financial data around the world without touching terrestrial networks. In his session at 20th Cloud Expo, Cliff Beek, President of Cloud Constellation Corporation, d...
IT organizations are moving to the cloud in hopes to approve efficiency, increase agility and save money. Migrating workloads might seem like a simple task, but what many businesses don’t realize is that application migration criteria differs across organizations, making it difficult for architects to arrive at an accurate TCO number. In his session at 21st Cloud Expo, Joe Kinsella, CTO of CloudHealth Technologies, will offer a systematic approach to understanding the TCO of a cloud application...
"With Digital Experience Monitoring what used to be a simple visit to a web page has exploded into app on phones, data from social media feeds, competitive benchmarking - these are all components that are only available because of some type of digital asset," explained Leo Vasiliou, Director of Web Performance Engineering at Catchpoint Systems, in this SYS-CON.tv interview at DevOps Summit at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
SYS-CON Events announced today that Secure Channels, a cybersecurity firm, will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Secure Channels, Inc. offers several products and solutions to its many clients, helping them protect critical data from being compromised and access to computer networks from the unauthorized. The company develops comprehensive data encryption security strategie...
SYS-CON Events announced today that WineSOFT will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Based in Seoul and Irvine, WineSOFT is an innovative software house focusing on internet infrastructure solutions. The venture started as a bootstrap start-up in 2010 by focusing on making the internet faster and more powerful. WineSOFT’s knowledge is based on the expertise of TCP/IP, VPN, S...
WebRTC is the future of browser-to-browser communications, and continues to make inroads into the traditional, difficult, plug-in web communications world. The 6th WebRTC Summit continues our tradition of delivering the latest and greatest presentations within the world of WebRTC. Topics include voice calling, video chat, P2P file sharing, and use cases that have already leveraged the power and convenience of WebRTC.
SYS-CON Events announced today that App2Cloud will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on Oct. 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. App2Cloud is an online Platform, specializing in migrating legacy applications to any Cloud Providers (AWS, Azure, Google Cloud).
The goal of Continuous Testing is to shift testing left to find defects earlier and release software faster. This can be achieved by integrating a set of open source functional and performance testing tools in the early stages of your software delivery lifecycle. There is one process that binds all application delivery stages together into one well-orchestrated machine: Continuous Testing. Continuous Testing is the conveyer belt between the Software Factory and production stages. Artifacts are m...
When shopping for a new data processing platform for IoT solutions, many development teams want to be able to test-drive options before making a choice. Yet when evaluating an IoT solution, it’s simply not feasible to do so at scale with physical devices. Building a sensor simulator is the next best choice; however, generating a realistic simulation at very high TPS with ease of configurability is a formidable challenge. When dealing with multiple application or transport protocols, you would be...
Cloud resources, although available in abundance, are inherently volatile. For transactional computing, like ERP and most enterprise software, this is a challenge as transactional integrity and data fidelity is paramount – making it a challenge to create cloud native applications while relying on RDBMS. In his session at 21st Cloud Expo, Claus Jepsen, Chief Architect and Head of Innovation Labs at Unit4, will explore that in order to create distributed and scalable solutions ensuring high availa...
An increasing number of companies are creating products that combine data with analytical capabilities. Running interactive queries on Big Data requires complex architectures to store and query data effectively, typically involving data streams, an choosing efficient file format/database and multiple independent systems that are tied together through custom-engineered pipelines. In his session at @BigDataExpo at @ThingsExpo, Tomer Levi, a senior software engineer at Intel’s Advanced Analytics ...
Internet-of-Things discussions can end up either going down the consumer gadget rabbit hole or focused on the sort of data logging that industrial manufacturers have been doing forever. However, in fact, companies today are already using IoT data both to optimize their operational technology and to improve the experience of customer interactions in novel ways. In his session at @ThingsExpo, Gordon Haff, Red Hat Technology Evangelist, shared examples from a wide range of industries – including en...
In IT, we sometimes coin terms for things before we know exactly what they are and how they’ll be used. The resulting terms may capture a common set of aspirations and goals – as “cloud” did broadly for on-demand, self-service, and flexible computing. But such a term can also lump together diverse and even competing practices, technologies, and priorities to the point where important distinctions are glossed over and lost.